Join us for a discussion led by James S. Manuso, Ph.D., past Chairman & CEO of Astex Pharmaceuticals. This presentation will review successes and failures of strategy, organization architecture and political engagement in the course of the development and growth of Astex Pharmaceuticals, from its foundation as SuperGen (formerly Supergenerics) in 1991 to 2013, when it was sold to Otsuka Pharmaceuticals for $886MM. A specific focus of the presentation will be on the period, 2003-2013, during which time a strategy of product approvals and targeted domestic and international acquisitions and divestitures of companies, compounds and discovery operations was executed, enabled by a series of financings and the revenue streams emanating from Nipent for Hairy Cell Leukemia and the approvals of Dacogen for Myelodysplastic Syndrome and AML.
The lessons learned from this decade-long process of corporate development will be addressed, along with their potential applicability to the challenges faced by many biopharma organizations today.
Dr. James Manuso is Chairman and CEO of Talfinium Investments, Inc., an investment entity and financial consultancy. Dr. Manuso previously served as Chairman and CEO of Astex Pharmaceuticals, Inc. (formerly SuperGen), from 2011 until 2013, at which time he sold the company to Otsuka Pharmaceuticals for $886MM. From 2004 to 2011 he served as Chairman, President and CEO of Astex. Dr. Manuso is co-founder and immediate past President and CEO of Galenica Pharmaceuticals, Inc. He co-founded and was General Partner of PrimeTech Partners, a biotechnology venture management partnership, and Managing General Partner of The Channel Group LLC, an international life sciences corporate advisory firm. Dr. Manuso was also President of Manuso, Alexander & Associates, Inc., management consultants and financial advisors to pharmaceutical and biotechnology companies.
Dr. Manuso serves on the board of KineMed, Inc. and previously served on the boards of The Biotechnology Industry Organization (BIO) and its Health Section Governing Board. He served on the boards of Novelos Therapeutics, Inc. (now Cellectar), Merrion Pharmaceuticals Ltd., Inflazyme Pharmaceuticals, Inc., and several other companies including EuroGen, Ltd. (London, UK), where he was Chairman.
Dr. Manuso earned a B.A. with Honors in Economics and Chemistry from New York University, a Ph.D. in Experimental Psychophysiology and Genetics from the Graduate Faculty of The New School University where he was a New School Scholar, a Certificate in Health Systems Management from Harvard Business School, and an Executive MBA from Columbia Business School where he was an Equitable Companies Scholar.
Dr. Manuso is the author of over 30 chapters, articles and books on topics including health care cost containment and biotechnology company management. He has taught and lectured at many universities and associations, and has served as Vice President and a member of the Board of Trustees of the Greater San Francisco Bay Area Leukemia & Lymphoma Society.